Prevalence and determinants of serum antibodies to SARS-CoV-2 in the general population of the Gardena valley.


Journal

Epidemiology and infection
ISSN: 1469-4409
Titre abrégé: Epidemiol Infect
Pays: England
ID NLM: 8703737

Informations de publication

Date de publication:
03 08 2021
Historique:
entrez: 14 10 2021
pubmed: 15 10 2021
medline: 26 10 2021
Statut: epublish

Résumé

Estimating the spread of SARS-CoV-2 infection in communities is critical. We surveyed 2244 stratified random sample community members of the Gardena valley, a winter touristic area, amidst the first expansion phase of the COVID-19 pandemic in Europe. We measured agreement between Diasorin and Abbott serum bioassay outputs and the Abbott optimal discriminant threshold of serum neutralisation titres with recursive receiver operating characteristic curve. We analytically adjusted serum antibody tests for unbiased seroprevalence estimate and analysed the determinants of infection with non-response weighted multiple logistic regression. SARS-CoV-2 seroprevalence was 26.9% (95% CI 25.2-28.6) by June 2020. The bioassays had a modest agreement with each other. At a lower threshold than the manufacturer's recommended level, the Abbott assay reflected greater discrimination of serum neutralisation capacity. Seropositivity was associated with place and economic activity, not with sex or age. Symptoms like fever and weakness were age-dependent. SARS-CoV-2 mitigation strategies should account for context in high prevalence areas.

Identifiants

pubmed: 34645534
doi: 10.1017/S0950268821001886
pii: S0950268821001886
pmc: PMC8387688
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Immunoglobulin G 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e194

Références

J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Cell. 2021 Jan 7;184(1):169-183.e17
pubmed: 33296701
Clin Microbiol Infect. 2021 Apr;27(4):633.e1-633.e7
pubmed: 33253941
Nat Commun. 2020 Nov 12;11(1):5749
pubmed: 33184277
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
Science. 2021 Jan 15;371(6526):288-292
pubmed: 33293339
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Cell Rep Med. 2020 Sep 22;1(6):100081
pubmed: 32839763
Emerg Microbes Infect. 2019;8(1):1593-1603
pubmed: 31711379
Circulation. 2020 Nov 3;142(18):1791-1793
pubmed: 32966752
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32580948
Clin Microbiol Infect. 2021 Mar;27(3):331-340
pubmed: 33228974
Am J Epidemiol. 1978 Jan;107(1):71-6
pubmed: 623091
Nature. 2020 Aug;584(7821):425-429
pubmed: 32604404
Biometrics. 1989 Mar;45(1):255-68
pubmed: 2720055
Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
N Engl J Med. 2020 Jun 11;382(24):2302-2315
pubmed: 32289214
N Engl J Med. 2020 Mar 26;382(13):1194-1196
pubmed: 32074416
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
Cell. 2020 Dec 10;183(6):1496-1507.e16
pubmed: 33171099
J Infect. 2020 Dec;81(6):e10-e12
pubmed: 32961253
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Respir Med. 2010 Feb;104(2):172-9
pubmed: 19857946
Int J Epidemiol. 2021 Jul 19;:
pubmed: 34293141

Auteurs

Roberto Melotti (R)

Institute for Biomedicine (affiliated to the University of Lübeck), Eurac Research, Bolzano, Italy.

Federica Scaggiante (F)

Laboratorio di Patologia Clinica di Bressanone, Hospital of Bressanone (SABES-ASDAA), Bressanone-Brixen, Italy.

Michela Falciani (M)

Servizio farmaceutico, Hospital of Bolzano (SABES-ASDAA), Bolzano-Bozen, Italy.

Christian X Weichenberger (CX)

Institute for Biomedicine (affiliated to the University of Lübeck), Eurac Research, Bolzano, Italy.

Luisa Foco (L)

Institute for Biomedicine (affiliated to the University of Lübeck), Eurac Research, Bolzano, Italy.

Stefano Lombardo (S)

Istituto provinciale di Statistica (ASTAT), Amministrazione Provincia Bolzano, Bolzano, Italy.

Alessandro De Grandi (A)

Institute for Biomedicine (affiliated to the University of Lübeck), Eurac Research, Bolzano, Italy.

Dorothee von Laer (D)

Institute of Virology, Department of Hygiene, Microbiology and Public Health at Innsbruck Medical University, Innsbruck, Austria.

Angelika Mahlknecht (A)

Istituto di Medicina Generale, Scuola Provinciale Superiore di Sanità (Claudiana), Bolzano, Italy.
Institute of General Practice, Family Medicine and Preventive Medicine, Paracelsus Medical University, Salzburg, Austria.

Peter P Pramstaller (PP)

Institute for Biomedicine (affiliated to the University of Lübeck), Eurac Research, Bolzano, Italy.

Elisabetta Pagani (E)

Laboratorio Aziendale di Microbiologia e Virologia, Hospital of Bolzano (SABES-ASDAA), Bolzano-Bozen, Italy.

Horand Meier (H)

Unità operativa governo clinico, Amministrazione Provincia Bolzano, Bolzano, Italy.

Timon Gaertner (T)

Istituto provinciale di Statistica (ASTAT), Amministrazione Provincia Bolzano, Bolzano, Italy.

Christina Troi (C)

Laboratorio di Patologia Clinica di Bressanone, Hospital of Bressanone (SABES-ASDAA), Bressanone-Brixen, Italy.

Deborah Mascalzoni (D)

Institute for Biomedicine (affiliated to the University of Lübeck), Eurac Research, Bolzano, Italy.
Centre for Research Ethics and Bioethics (CRB), Department for Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.

Cristian Pattaro (C)

Institute for Biomedicine (affiliated to the University of Lübeck), Eurac Research, Bolzano, Italy.

Michael Mian (M)

Service for Innovation, Research and Teaching, Hospital of Bolzano (SABES-ASDAA), Bolzano-Bozen, Italy.
Scuola Provinciale Superiore di Sanità (Claudiana), Bolzano, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH